Related references
Note: Only part of the references are listed.Network meta-analysis: an introduction for clinicians
Benjamin Rouse et al.
INTERNAL AND EMERGENCY MEDICINE (2017)
Treatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis
Liang Wang et al.
ONCOTARGETS AND THERAPY (2017)
Survival benefit of anti-angiogenic agents in patients with previously treated advanced gastric or gastroesophageal junction cancer: a meta-analysis
Jung Han Kim et al.
ONCOTARGET (2017)
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma The METGastric Randomized Clinical Trial
Manish A. Shah et al.
JAMA ONCOLOGY (2017)
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial
H. H. Yoon et al.
ANNALS OF ONCOLOGY (2016)
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
Markus Moehler et al.
BMC CANCER (2016)
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Jin Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial
Nick Pavlakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction
Manish A. Shah et al.
ONCOLOGIST (2016)
Rilotumumab Exposure-Response Relationship in Patients with Advanced or Metastatic Gastric Cancer
Sameer Doshi et al.
CLINICAL CANCER RESEARCH (2015)
Survival Analysis of Patients with Interval Cancer Undergoing Gastric Cancer Screening by Endoscopy
Chisato Hamashima et al.
PLOS ONE (2015)
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)
Lin Shen et al.
GASTRIC CANCER (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Effects of Fluroquinolones in Newly Diagnosed, Sputum-Positive Tuberculosis Therapy: A Systematic Review and Network Meta-Analysis
Dandan Li et al.
PLOS ONE (2015)
The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey
Giuseppe Aprile et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs et al.
LANCET (2014)
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
Timothy Iveson et al.
LANCET ONCOLOGY (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer
M. M. Eatock et al.
ANNALS OF ONCOLOGY (2013)
Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial
Jin Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Adjustment for reporting bias in network meta-analysis of antidepressant trials
Ludovic Trinquart et al.
BMC MEDICAL RESEARCH METHODOLOGY (2012)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
The interpretation of random-effects meta-analysis in decision models
AE Ades et al.
MEDICAL DECISION MAKING (2005)
Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial
SR Bramhall et al.
BRITISH JOURNAL OF CANCER (2002)
Share Paper
